Pfizer, Inc. · NYSE:PFE
Pfizer — 28th Annual J.P. Morgan Healthcare Conference (January 2010)
20 slides from Pfizer's conference presentation, Jan 12, 2010
Slide 1: Delivering High Impact Medicines That Transform Patients Lives
Delivering High Impact Medicines That Transform Patients Lives Martin Mackay, President PharmaTherapeutics JP Morgan January 2010
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2008 Annual Report on Form 10-K and i
Slide 3: Operating Model
Operating Model Nine Diverse Business Units Supported by Two Research Organizations PharmaTherapeutics BioPharmaceutical Businesses Research & Development Primary Specialty Established Emerging Oncology Care Care Products Markets BioTherapeutics Diversified Businesses Research & Development Consumer
Slide 4: The New R&D Organization
The New R&D Organization R&D biomedical presence in US, Europe, Canada and China 5 Major sites Footprint 9 Specialized units Reduced site footprint by 35% Closed 6 R&D sites/consolidated 4 R&D sites Invest to Win Projects increased 50% to 70% Portfolio Research portfolio prioritization
Slide 5: Innovative Therapies In Key Areas Of Unmet Medical Need
Innovative Therapies In Key Areas Of Unmet Medical Need Neuroscience Pain/Inflammation Oncology Metabolic Disorders Our Focus Is on High Priority Disease Areas and Enhanced Biologics Capabilities Vaccines Infectious Diseases Biotherapeutics 5
Slide 6: Early Stage: Human Genetics & Cell Biology Are Revolutionizing Target Selection
Early Stage: Human Genetics & Cell Biology Are Revolutionizing Target Selection Molecular Profiling Stem Cells Systems Biology Target Selection Human Genetics Bioimaging 6
Slide 7: NaV1.7: Exciting New Pain Target
NaV1.7: Exciting New Pain Target NaV 1.7 channel modulator will reduce pain by limiting Hypothesis the frequency of firing of pain sensing nerves Sodium channels responsible for detection and conduction of pain Human clinical genetic NaV 1.7 mutations have extreme pain phenotypes CIP Erythrome
Slide 8: Today's Phase 3 Portfolio
Today’s Phase 3 Portfolio apixaban – VTE Prevention CP-690,550 – Rheumatoid Arthritis Thelin – Pulmonary Hypertension Zithromax/chloro – Malaria Dimebon – Alzheimer’s Disease tanezumab – OA Pain figitumumab – Lung Cancer bosutinib – Chronic Myelogenous Leukemia NMEs bapineuzumab –
Slide 9: Select Late Stage Candidates
Select Late Stage Candidates Prevnar 13 for Adults (Vaccine) Vaccine Tanezumab (NGF Antibody) Pain CP-690550 (JAK3 Inhibitor) Rheumatoid Arthritis Dimebon (MPTP Modulator) Alzheimer’s Disease Bapineuzumab (IV Pass Mono Antibody) Alzheimer’s Disease PF-2341066 (c-Met/ALK Inhibitor) NSCLC
Slide 10: Prevnar 13: Expanding The Opportunity
™: Expanding The Opportunity Prevnar 13™ Infant Adult Provide Broadest Coverage Provide First and Only Available for the Global Conjugate Vaccine That Protection of Children Offers Adults, >50, an Opportunity Against Pneumococcal Opportunity to Prevent Disease Pneumococcal Pneumonia for the Rest
Slide 11: Pain Therapeutics: Broad Mechanistic Approach, Multiple Modalities
Pain Therapeutics: Broad Mechanistic Approach, Multiple Modalities 1 Peripheral Sensitization Celebrex (gout, Ph3b) Tanezumab (Ph3) CGRP antibody (migraine, Ph1) Peripheral u opioid agonist (LD) 4 2 Pain Transduction & Conduction Nav1.7 blocker (LD) Nav1.8 blocker (Ph1, SDS) TrpV1 bloc
Slide 12: Tanezumab: Pain Responder Rates
Tanezumab: Pain Responder Rates Osteoarthritis 100% 90% *** 80% *** Placebo (n=73) *** Percent of Patients 70% * *** tanezumab 10 g/kg (n=73) 60% * tanezumab 25 g/kg (n=75) 50% tanezumab 50 g/kg (n=72) 40% 30% tanezumab 100 g/kg (n=74) 20% tanezumab 200 g/kg (n=72) 10% 0% 30% Responders 50% Res
Slide 13: CP-690,550: RA Phase 2 Program Conclusions
CP-690,550: RA Phase 2 Program Conclusions 4/4 studies achieved statistical significance on the primary endpoint (ACR20 Response) Extensive Phase 2 RA Program enrolled >1,000 patients and explored a CP-690,550 dose range of 1 to 30 mg BID CP-690,550 dosed 3 mg BID was generally efficacious,
Slide 14: Multiple Approaches To Treat AD Spanning Small Molecules, Biologics, And Vaccines
Multiple Approaches To Treat AD Spanning Small Molecules, Biologics, And Vaccines 4 Amyloid Pathway 7 5 1 Anti-A antibody (Ph 3, Ph 2, PC) 2 Anti-A vaccine (Ph 2) 1 2 3 RAGE antagonist (Ph 2) 3 4 -Secretase inhibitor (Ph 1, LD) 5 BACE inhibitor (LD) 1 2 Tau Pathway 6 6 Tau vaccine (LD) 1 2 Modula
Slide 15: Dimebon: Affects Cognition In Mild-To-Moderate AD
Dimebon: Affects Cognition In Mild-To-Moderate AD Treatment p = 0.0077 p < 0.0001 p < 0.0001 p < 0.0001 Effect 2.0 4.0 5.9 6.9 –3.0 Mean Change From Baseline –2.0 Clinical –1.0 Improvement Score ADS-cog 0.0 1.0 2.0 3.0 4.0 5.0 Dimebon (n = 89) Clinical 6.0 Deterioration Placebo (n = 94) Baseline 12
Slide 16: Bapineuzumab: Alzheimer's Disease
Bapineuzumab: Alzheimer’s Disease Four Studies in Over 4,000 Patients Worldwide Patients Are Stratified by ApoE4 Carriers vs. Non-Carriers Co-Primary Efficacy Endpoints – Validated Cognitive and Functional Scales Phase 2 Data Presented at ICAD – July 2008 Safety and Efficacy Findings Suppo
Slide 17: PF-2341066: NSCLC
PF-2341066: NSCLC Novel c-Met/ALK Inhibitor is the First Agent in Clinical Development to Selectively Target Sub-group of NSCLC Patients ASCO 2009 – Presented new study results from an expansion cohort of a Phase 1 study in patients with NSCLC carrying the ALK (anaplastic lymphoma kinases) fusio
Slide 18: PF-2341066 (cMet Alk) Pre-Treatment (FLT-PET)
PF-2341066 (cMet Alk) 43 yr old Male with Stage IV NSCLC positive for EML4-ALK Pre-Treatment (FLT-PET) After 1 Cycle PF-2341066 18
Slide 19: Working Together To Progress Assets, Programs And Technologies
Working Together To Progress Assets, Programs And Technologies Areas of Interest Types of Relationships Alzheimer’s Biotherapeutics Licensing Disease Vaccines Co-develop/Co-promote Diabetes Biomarkers Alliances Inflammation & Regenerative Medicine Venture Investments Immunology Consumer Healthcare M
Slide 20: Drug Discovery Heroes Heart of What We Do
Drug Discovery Heroes Vaccine Expertise Heart of What We Do Neuroscience Expertise 20
Pfizer — 28th Annual J.P. Morgan Healthcare Conference (January 2010) on 6ix